btov Partners is a European venture capital firm focusing on technology startups since 2000, supported by a community of entrepreneurial private investors.
The Series C round was co-led by R42 Group and Atomico to support clinical trials for rare disease treatments.
"It is truly a pivotal time at Healx. By December 2024, we will advance HLX-1502 into a Phase 2 clinical trial in patients with NF1 both for plexiform neurofibroma, a genetic condition with limited treatment options and for cutaneous neurofibroma, for which there are no FDA approved options. We are also generating important preclinical data for multiple additional compounds identified using our novel generative AI drug discovery engine. Those compounds target rare diseases with significant unmet needs, including additional nerve-related tumor disorders, autosomal dominant polycystic kidney disease and neurodevelopmental disorders such as Angelman syndrome."
The Series B round was led by Beringea to support platform growth and expansion across the US and Europe.
"Customers today share vast amounts of feedback online across a wealth of platforms and channels, providing a huge opportunity for businesses to drive performance through customer insight. However, the current solutions in the market lack flexibility and accuracy when analysing this unstructured customer feedback across a wide range of sectors. Chattermill has, therefore, enabled a blue-chip roster of clients to tap into a ‘data gold mine’ that had previously been out of reach – the highly-scalable, intuitive product that Mikhail, Dmitry, and their exceptional team is demonstrating immense opportunity as proven by their rapid growth."
The funding round was led by Bain Capital Tech Opportunities and values the company at €8bn.
"Our ability to organically grow 60+% through the challenges of recent years shows that we are there for merchants when they need support most. I am very proud of the team for completing a successful financing round in the current market with marquee investors – it’s indicative of our strength, execution, and potential. The funds we’ve raised will enable us to continue to build out our product ecosystem, expand into new markets, pursue value-adding acquisitions, and continue leveling the playing field for small merchants at a global scale."
The London-based marketplace secured backing from btov Partners to scale its digital renovation platform across the UK.
"We have been focused on building a platform for home renovation that not only serves an imminent need but will deliver even more value as we scale. Very few industries are as behind as the construction industry, and we are poised to become a game changer that can make home renovation much easier, less risky, and more cost-effective for contractors, architects and homeowners alike."
The financing round was led by Glenview Capital and co-led by Novo Holdings.
"Everybody knows that dialysis care must improve. For this to happen, providers and physicians need products that allow greater flexibility to bring dialysis directly to the patient, while simplifying complexity and reducing the overall cost of care. Our small, simple-to-use, and powerful dialysis system SC+ is positioned to help transform kidney care. The funding we are announcing today will allow us to accelerate our emergence as a significant force in this market."
